23:00 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies identified an inhibitor of the transmembrane domain of p75 NTR that could help treat melanoma. Screening of a compound library in a binding assay in bacteria expressing the...
17:08 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Coherus plans to resubmit BLA for Neulasta biosimilar

In its FY17 earnings, Coherus BioSciences Inc. (NASDAQ:CHRS) said it will resubmit a BLA for CHS-1701, with plans to launch the product in the U.S. next half. The company, which in November had said it...
23:44 , Mar 9, 2018 |  BC Extra  |  Company News

Coherus gains on plans to resubmit BLA for Neulasta biosimilar

Coherus BioSciences Inc. (NASDAQ:CHRS) rose $2.75 (30%) to $11.85 on Friday after announcing in its earnings that it will resubmit a BLA for CHS-1701, with plans to launch the product in the U.S. next half....
20:17 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Benepali etanercept less immunogenic than reference product in Phase III

A research letter published in the...
01:53 , Jan 25, 2018 |  BC Innovations  |  Translation in Brief

No TNFα for transplants

A University of Toronto team has shown that inhibiting TNFα enhances the engraftment success of hematopoietic stem cell transplants in mice and plans to test the strategy in the clinic using Enbrel etanercept within a...
20:42 , Dec 15, 2017 |  BC Week In Review  |  Financial News

Clover raises RMB62.8M in series A

On Dec. 14, Clover Biopharmaceuticals Inc. (Chengdu, China) raised RMB62.8 million ($9.5 million) in a series A round led by new investor Tianhe Life Sciences Venture Fund. Clover is developing covalently trimerized fusion proteins using...
21:10 , Dec 14, 2017 |  BC Extra  |  Financial News

Clover raises RMB62.8M in series A

Clover Biopharmaceuticals Inc. (Chengdu, China) raised RMB62.8 million ($9.5 million) in a series A round led by Tianhe Life Sciences Venture Fund. Clover is developing covalently trimerized fusion proteins using its Timer-Tag technology to target...
20:27 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

Levicept begins Phase I of fusion protein for chronic pain

Levicept Ltd. (Sandwich, U.K.) began a Phase I trial to evaluate single ascending doses of its chronic pain candidate IV LEVI-04 (p75NTR-Fc) in healthy volunteers and in patients with pain due to osteoarthritis (OA) of...
22:17 , Sep 14, 2017 |  BC Extra  |  Clinical News

Levicept begins Phase I of fusion protein for chronic pain

Levicept Ltd. (Sandwich, U.K.) began a Phase I trial of its chronic pain candidate IV LEVI-04 (p75NTR-Fc) in healthy volunteers and in patients with pain due to osteoarthritis (OA) of the knee. LEVI-04 is a...
20:35 , Jul 21, 2017 |  BC Week In Review  |  Company News

NICE recommends psoriasis drugs Humira, Enbrel and Stelara in final guidance

The U.K.'s NICE issued final guidance for three plaque psoriasis drugs in specific populations of children and young people experiencing severe disease who have not responded to standard systemic therapy. NICE said severe is defined...